Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OT0MVBM6)

• DOT Name: Metallothionein-1H (MT1H)
• Synonyms: MT-1H; Metallothionein-0; MT-0; Metallothionein-IH; MT-IH
• Gene Name: MT1H
• Related Disease:
  Advanced cancer
  Amyotrophic lateral sclerosis type 1
  Androgen insensitivity syndrome
  Breast cancer
  Breast carcinoma
  Carcinoma of liver and intrahepatic biliary tract
  Classic Hodgkin lymphoma
  Clear cell renal carcinoma
  Colonic neoplasm
  Creutzfeldt Jacob disease
  Glioma
  Graves disease
  Hepatocellular carcinoma
  Huntington disease
  Laryngeal carcinoma
  Laryngeal squamous cell carcinoma
  Liver cancer
  Lymphosarcoma
  Malignant pleural mesothelioma
  Metastatic malignant neoplasm
  Nephritis
  Renal cell carcinoma
  Systemic lupus erythematosus
  Lung cancer
  Lung carcinoma
  Non-small-cell lung cancer
  Breast neoplasm
  Glaucoma/ocular hypertension
  Lupus nephritis
  Non-insulin dependent diabetes
  Prostate cancer
  Prostate carcinoma
  Stroke
• UniProt ID: MT1H_HUMAN
• Pfam ID: PF00131
• Sequence:
  MDPNCSCEAGGSCACAGSCKCKKCKCTSCKKSCCSCCPLGCAKCAQGCICKGASEKCSCC
  A
• Function: Metallothioneins have a high content of cysteine residues that bind various heavy metals; these proteins are transcriptionally regulated by both heavy metals and glucocorticoids.
• KEGG Pathway: Mineral absorption (hsa04978)
• Reactome Pathway: Metallothioneins bind metals (R-HSA-5661231)

Molecular Interaction Atlas (MIA) of This DOT

33 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Advanced cancer	DISAT1Z9	Strong	Biomarker	[1]
Amyotrophic lateral sclerosis type 1	DIS5A2M0	Strong	Biomarker	[2]
Androgen insensitivity syndrome	DISUZBBO	Strong	Altered Expression	[3]
Breast cancer	DIS7DPX1	Strong	Biomarker	[4]
Breast carcinoma	DIS2UE88	Strong	Biomarker	[4]
Carcinoma of liver and intrahepatic biliary tract	DIS8WA0W	Strong	Altered Expression	[5]
Classic Hodgkin lymphoma	DISV1LU6	Strong	Genetic Variation	[6]
Clear cell renal carcinoma	DISBXRFJ	Strong	Biomarker	[7]
Colonic neoplasm	DISSZ04P	Strong	Posttranslational Modification	[8]
Creutzfeldt Jacob disease	DISCB6RX	Strong	Biomarker	[9]
Glioma	DIS5RPEH	Strong	Biomarker	[10]
Graves disease	DISU4KOQ	Strong	Biomarker	[11]
Hepatocellular carcinoma	DIS0J828	Strong	Altered Expression	[12]
Huntington disease	DISQPLA4	Strong	Altered Expression	[13]
Laryngeal carcinoma	DISNHCIV	Strong	Biomarker	[14]
Laryngeal squamous cell carcinoma	DIS9UUVF	Strong	Biomarker	[14]
Liver cancer	DISDE4BI	Strong	Altered Expression	[5]
Lymphosarcoma	DISGYV3F	Strong	Posttranslational Modification	[15]
Malignant pleural mesothelioma	DIST2R60	Strong	Biomarker	[1]
Metastatic malignant neoplasm	DIS86UK6	Strong	Altered Expression	[5]
Nephritis	DISQZQ70	Strong	Altered Expression	[16]
Renal cell carcinoma	DISQZ2X8	Strong	Biomarker	[7]
Systemic lupus erythematosus	DISI1SZ7	Strong	Altered Expression	[16]
Lung cancer	DISCM4YA	moderate	Genetic Variation	[17]
Lung carcinoma	DISTR26C	moderate	Genetic Variation	[17]
Non-small-cell lung cancer	DIS5Y6R9	Disputed	Altered Expression	[18]
Breast neoplasm	DISNGJLM	Limited	Altered Expression	[19]
Glaucoma/ocular hypertension	DISLBXBY	Limited	Genetic Variation	[20]
Lupus nephritis	DISCVGPZ	Limited	Altered Expression	[16]
Non-insulin dependent diabetes	DISK1O5Z	Limited	Altered Expression	[21]
Prostate cancer	DISF190Y	Limited	Altered Expression	[22]
Prostate carcinoma	DISMJPLE	Limited	Altered Expression	[22]
Stroke	DISX6UHX	Limited	Biomarker	[23]

27 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate increases the expression of Metallothionein-1H (MT1H).	[24]
Acetaminophen	DMUIE76	Approved	Acetaminophen increases the expression of Metallothionein-1H (MT1H).	[25]
Cupric Sulfate	DMP0NFQ	Approved	Cupric Sulfate decreases the expression of Metallothionein-1H (MT1H).	[26]
Cisplatin	DMRHGI9	Approved	Cisplatin affects the expression of Metallothionein-1H (MT1H).	[27]
Estradiol	DMUNTE3	Approved	Estradiol decreases the expression of Metallothionein-1H (MT1H).	[28]
Arsenic trioxide	DM61TA4	Approved	Arsenic trioxide increases the expression of Metallothionein-1H (MT1H).	[29]
Hydrogen peroxide	DM1NG5W	Approved	Hydrogen peroxide increases the expression of Metallothionein-1H (MT1H).	[30]
Decitabine	DMQL8XJ	Approved	Decitabine affects the expression of Metallothionein-1H (MT1H).	[27]
Progesterone	DMUY35B	Approved	Progesterone increases the expression of Metallothionein-1H (MT1H).	[31]
Menadione	DMSJDTY	Approved	Menadione increases the expression of Metallothionein-1H (MT1H).	[30]
Dexamethasone	DMMWZET	Approved	Dexamethasone increases the expression of Metallothionein-1H (MT1H).	[32]
Demecolcine	DMCZQGK	Approved	Demecolcine increases the expression of Metallothionein-1H (MT1H).	[33]
Cannabidiol	DM0659E	Approved	Cannabidiol increases the expression of Metallothionein-1H (MT1H).	[34]
Obeticholic acid	DM3Q1SM	Approved	Obeticholic acid decreases the expression of Metallothionein-1H (MT1H).	[35]
Acetic Acid, Glacial	DM4SJ5Y	Approved	Acetic Acid, Glacial increases the expression of Metallothionein-1H (MT1H).	[36]
Motexafin gadolinium	DMEJKRF	Approved	Motexafin gadolinium increases the expression of Metallothionein-1H (MT1H).	[37]
SNDX-275	DMH7W9X	Phase 3	SNDX-275 increases the expression of Metallothionein-1H (MT1H).	[38]
Epigallocatechin gallate	DMCGWBJ	Phase 3	Epigallocatechin gallate decreases the expression of Metallothionein-1H (MT1H).	[39]
Amiodarone	DMUTEX3	Phase 2/3 Trial	Amiodarone increases the expression of Metallothionein-1H (MT1H).	[40]
Phenol	DM1QSM3	Phase 2/3	Phenol decreases the expression of Metallothionein-1H (MT1H).	[41]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene decreases the expression of Metallothionein-1H (MT1H).	[42]
PMID28460551-Compound-2	DM4DOUB	Patented	PMID28460551-Compound-2 increases the expression of Metallothionein-1H (MT1H).	[43]
Milchsaure	DM462BT	Investigative	Milchsaure increases the expression of Metallothionein-1H (MT1H).	[44]
Hexadecanoic acid	DMWUXDZ	Investigative	Hexadecanoic acid decreases the expression of Metallothionein-1H (MT1H).	[45]
Phencyclidine	DMQBEYX	Investigative	Phencyclidine increases the expression of Metallothionein-1H (MT1H).	[46]
Okadaic acid	DM47CO1	Investigative	Okadaic acid increases the expression of Metallothionein-1H (MT1H).	[47]
Lead acetate	DML0GZ2	Investigative	Lead acetate increases the expression of Metallothionein-1H (MT1H).	[48]

References

• [1] Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.Oncotarget. 2018 Apr 27;9(32):22254-22268. doi: 10.18632/oncotarget.24962. eCollection 2018 Apr 27.
• [2] Reduction of metallothioneins promotes the disease expression of familial amyotrophic lateral sclerosis mice in a dose-dependent manner.Eur J Neurosci. 2001 Apr;13(7):1363-70. doi: 10.1046/j.0953-816x.2001.01512.x.
• [3] Abnormal melatonin receptor 1B expression in osteoblasts from girls with adolescent idiopathic scoliosis.J Pineal Res. 2011 May;50(4):395-402. doi: 10.1111/j.1600-079X.2011.00857.x. Epub 2011 Feb 24.
• [4] A case-control study of Metallothionein-1 expression in breast cancer and breast fibroadenoma.Sci Rep. 2019 May 15;9(1):7407. doi: 10.1038/s41598-019-43565-0.
• [5] Metallothionein 1 h tumour suppressor activity in prostate cancer is mediated by euchromatin methyltransferase 1.J Pathol. 2013 Jun;230(2):184-93. doi: 10.1002/path.4169.
• [6] A novel MspI PCR-RFLP in the human cytosine 5-methyltransferase gene: lack of relevance for malignant lymphoproliferative disease and breast cancer.Hum Hered. 1998 Jul-Aug;48(4):226-9. doi: 10.1159/000022805.
• [7] In vivo gene expression profile analysis of metallothionein in renal cell carcinoma.Cancer Lett. 2000 Nov 28;160(2):133-40. doi: 10.1016/s0304-3835(00)00534-6.
• [8] Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line.Proc Natl Acad Sci U S A. 1992 May 15;89(10):4495-9. doi: 10.1073/pnas.89.10.4495.
• [9] Differential expression of metallothioneins in human prion diseases.Dement Geriatr Cogn Disord. 2000 Sep-Oct;11(5):251-62. doi: 10.1159/000017247.
• [10] The melatonin-MT1 receptor axis modulates tumor growth in PTEN-mutated gliomas.Biochem Biophys Res Commun. 2018 Feb 19;496(4):1322-1330. doi: 10.1016/j.bbrc.2018.02.010.
• [11] Expression of Metallothionein I/II and Ki-67 Antigen in Graves' Disease.Anticancer Res. 2018 Dec;38(12):6847-6853. doi: 10.21873/anticanres.13059.
• [12] Regulator of G-protein signaling 5 enhances portal vein invasion in hepatocellular carcinoma.Oncol Lett. 2018 Feb;15(2):1763-1770. doi: 10.3892/ol.2017.7474. Epub 2017 Nov 23.
• [13] The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity.J Neurosci. 2011 Oct 12;31(41):14496-507. doi: 10.1523/JNEUROSCI.3059-11.2011.
• [14] Potential biomarkers for head and neck squamous cell carcinoma.Laryngoscope. 2003 Mar;113(3):393-400. doi: 10.1097/00005537-200303000-00001.
• [15] Physical and functional interaction of DNA methyltransferase 3A with Mbd3 and Brg1 in mouse lymphosarcoma cells.Cancer Res. 2005 Dec 1;65(23):10891-900. doi: 10.1158/0008-5472.CAN-05-1455.
• [16] The renal metallothionein expression profile is altered in human lupus nephritis.Arthritis Res Ther. 2008;10(4):R76. doi: 10.1186/ar2450. Epub 2008 Jul 6.
• [17] Impact of metallothionein gene polymorphisms on the risk of lung cancer in a Japanese population.Mol Carcinog. 2015 Jun;54 Suppl 1:E122-8. doi: 10.1002/mc.22198. Epub 2014 Aug 30.
• [18] Metallothionein 1F and 2A overexpression predicts poor outcome of non-small cell lung cancer patients.Exp Mol Pathol. 2013 Feb;94(1):301-8. doi: 10.1016/j.yexmp.2012.10.006. Epub 2012 Oct 9.
• [19] Immunohistochemical Expression of Melatonin Receptor MT1 and Glucose Transporter GLUT1 in Human Breast Cancer.Anticancer Agents Med Chem. 2018;18(15):2110-2116. doi: 10.2174/1871520618666181025125532.
• [20] Variations in the myocilin gene in patients with open-angle glaucoma.Arch Ophthalmol. 2002 Sep;120(9):1189-97. doi: 10.1001/archopht.120.9.1189.
• [21] Metallothionein-mediated antioxidant defense system and its response to exercise training are impaired in human type 2 diabetes.Diabetes. 2005 Nov;54(11):3089-94. doi: 10.2337/diabetes.54.11.3089.
• [22] Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-B): potential implications on prostate cancer chemoprevention and therapy.J Pineal Res. 2013 Jan;54(1):69-79. doi: 10.1111/j.1600-079X.2012.01026.x. Epub 2012 Aug 1.
• [23] Metallothionein I as a direct link between therapeutic hematopoietic stem/progenitor cells and cerebral protection in stroke.FASEB J. 2018 May;32(5):2381-2394. doi: 10.1096/fj.201700746R. Epub 2017 Dec 21.
• [24] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [25] Gene expression changes associated with cytotoxicity identified using cDNA arrays. Funct Integr Genomics. 2000 Sep;1(2):114-26.
• [26] Extremely low copper concentrations affect gene expression profiles of human prostate epithelial cell lines. Chem Biol Interact. 2010 Oct 6;188(1):214-9.
• [27] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [28] Human drug metabolism genes in parathion-and estrogen-treated breast cells. Int J Mol Med. 2007 Dec;20(6):875-81.
• [29] Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
• [30] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [31] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [32] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [33] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [34] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [35] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [36] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [37] Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res. 2005 May 1;65(9):3837-45.
• [38] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [39] Application of the adverse outcome pathway concept for investigating developmental neurotoxicity potential of Chinese herbal medicines by using human neural progenitor cells in vitro. Cell Biol Toxicol. 2023 Feb;39(1):319-343. doi: 10.1007/s10565-022-09730-4. Epub 2022 Jun 15.
• [40] Capturing time-dependent activation of genes and stress-response pathways using transcriptomics in iPSC-derived renal proximal tubule cells. Cell Biol Toxicol. 2023 Aug;39(4):1773-1793. doi: 10.1007/s10565-022-09783-5. Epub 2022 Dec 31.
• [41] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [42] Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
• [43] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [44] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [45] Identification of palmitate-regulated genes in HepG2 cells by applying microarray analysis. Biochim Biophys Acta. 2007 Sep;1770(9):1283-8. doi: 10.1016/j.bbagen.2007.07.001. Epub 2007 Jul 10.
• [46] Differential response of Mono Mac 6, BEAS-2B, and Jurkat cells to indoor dust. Environ Health Perspect. 2007 Sep;115(9):1325-32.
• [47] Whole genome mRNA transcriptomics analysis reveals different modes of action of the diarrheic shellfish poisons okadaic acid and dinophysis toxin-1 versus azaspiracid-1 in Caco-2 cells. Toxicol In Vitro. 2018 Feb;46:102-112.
• [48] Analysis of lead toxicity in human cells. BMC Genomics. 2012 Jul 27;13:344.